Arjun Agarwal, who serves as the Senior Vice President of Finance at Oruka Therapeutics, Inc. (NASDAQ: ORKA), finalized the sale of common stock valued at approximately $846,180 on July 13, 2026. The liquidation involved the disposal of 10,999 shares. The execution prices for these shares varied between $83.07 and $85.63 per unit.
These sales were structured under a Rule 10b5-1 trading plan that Agarwal established on February 11, 2026. The execution of this plan coincides with a period where ORKA shares are trading in close proximity to their 52-week high of $97.78. This price level follows a significant appreciation of 510% over the preceding year. Valuation metrics from InvestingPro suggest the stock may currently be trading above its Fair Value, with the company maintaining a market capitalization of $5.1 billion.
Concurrently on July 13, 2026, Agarwal acquired an additional 9,999 shares of Oruka Therapeutics common stock. These shares were obtained through the exercise of employee stock options. The exercise prices for these options ranged from $12.50 to $34.39 per share, resulting in a total transaction value of approximately $156,903. The underlying options provide the right to purchase common stock and are scheduled to vest on a monthly basis over a 48-month period commencing from their respective grant dates.
Following the completion of these transactions, Agarwal's direct holdings in Oruka Therapeutics common stock stand at 15,312 shares. Additionally, he retains a position of 61,250 employee stock options. These holdings reflect the executive's direct equity exposure and potential future liquidity events tied to the company's performance.
Oruka Therapeutics has recently been the subject of multiple analyst updates and corporate developments that influence the broader biotech sector. UBS adjusted its price target for Oruka Therapeutics upward to $130, while maintaining a Buy rating. This adjustment is driven by positive expectations regarding upcoming efficacy data from the company's clinical pipeline.
H.C. Wainwright has also reiterated its Buy rating for Oruka Therapeutics, setting a price target of $120. This action follows the acquisition announcement by AbbVie of Apogee Therapeutics. The Apogee acquisition involves a pipeline of candidates targeting inflammatory and immunological diseases, a development that may alter the competitive landscape for firms like Oruka.
Furthermore, Oruka Therapeutics has amended its IL-23 license agreement with Paragon Therapeutics. This amendment has been highlighted by both H.C. Wainwright and Piper Sandler. Piper Sandler reaffirmed its Overweight rating with a price target of $180, noting that the amendment facilitates expanded development opportunities. Recent trial results for Oruka's EVERLAST-A trial, which investigates treatment for moderate-to-severe psoriasis, showed promising outcomes. Specifically, 63.5% of participants achieved PASI 100 at Week 16.
These developments indicate a period of strategic adjustments and positive clinical data for Oruka Therapeutics, as observed by several analyst firms covering the biotechnology sector.